Pseudorabies virus (PRV) is an alpha herpesvirus causing a natural infection in swine similar to that of herpes simplex virus in humans (4, 8) . Because the disease in swine is of economic importance, there has been considerable effort to control this problem through vaccination programs. Accordingly, there has been an increased effort to develop attenuated live vaccine strains. These attenuated PRV strains have been studied in detail by a number of laboratories to understand the general mechanisms of herpesvirus virulence (1-3, 5, 7, 10, 11, 13, 14, 20, 21) .
PRV strain Bartha (PRV-Ba) is a well-known attenuated vaccine strain (1) and is the basis for the Duvaxyn vaccine sold in Europe (21) . Although this strain grows well in culture, it harbors a number of mutations, some of which have been shown to contribute to its avirulent phenotype. For example, PRV-Ba contains a deletion in the unique short region removing coding sequences for glycoproteins gI and gp63 (11, 14) . Mettenleiter et al. (13) proved that glycoprotein gI played a major role in virulence but that it did so in conjunction with at least one other undefined viral function. These workers also demonstrated that the absence of gI affects virus release from certain cell types (12) . Lomniczi et al. (10) noted that the BamHI 4 fragment of PRV-Ba encoding four genes involved in capsid assembly contained defects contributing to the lack of virulence.
The subject of this report is the characterization of another defect in PRV-Ba, the reduced amount of glycoprotein gIll found in the virus envelope (2, 20) . To explain this observa-tion, Ben-Porat et al. (2) have suggested that PRV-Ba gIII is expressed in lesser amounts. We describe experiments using gene replacement technology to prove first that the expression defect is closely linked to the glll gene itself and second that it is not mediated at the level of transcription, but rather reflects a defect in protein localization, most likely due to a signal sequence mutation. Given that the gIll protein plays an important role in virus adsorption (20) and release (18, 20, 22) , as well as being a major immunogen (2, 9) , it is likely that the defective localization phenotype is yet another deficiency contributing to the avirulence of PRV-Ba.
MATERIALS AND METHODS
Cells, virus, and DNA. The growth and properties of the Becker strain of PRV (PRV-Be) and the porcine kidney cell line PK15 have been previously described (16) . PRV-Ba and PRV strain Ka (PRV-Ka) were generous gifts from T. Ben-Porat.
Cloning of the PstI fragments containing the gIll gene from PRV-Be, PRV-Ba, and PRV-Ka into Escherichia coli pBR322 plasmids was done as described previously (17) . The structure of each plasmid was verified by restriction endonuclease analysis.
Construction of isogenic set of PRV-Be strains containing gIlI gene of PRV-Ba and PRV-Ka. Recombinant viruses were obtained by the calcium phosphate cotransfection and gene replacement techniques described previously (17, 18 (17) . It pair (bp) XhoI fragment removing 230 bp of the upstream glll promoter region and 87% of the gIll coding sequence. PRV10 produces no detectable glll protein and forms a nonreactive or white plaque in the black-plaque assay with glll-specific antibodies followed by a peroxidase-linked second antibody (17) . In the same assay, Ml antibody gives reactive or black plaques for the parental PRV-Be, PRV-Ba, and PRV-Ka. After cotransfection, virus plaques were screened in the black-plaque assay for production of the parental glll protein. With monoclonal antibody Ml, black plaques were found at frequencies of 5% or more from all three cotransfection lysates, and one such black-plaque recombinant from each was picked for further analysis. Viruses were named as follows: PRV20 (glll gene of PRVBe), PRV21 (gIII gene of PRV-Ka), and PRV22 (glll gene of PRV-Ba). In these three recombinant viruses, we can be confident that at least the 1,480-bp XhoI fragment lacking in PRV10 has been replaced by DNA provided by the cloned PstI fragment. It is highly likely that more DNA upstream and downstream of the XhoI fragment also has been replaced.
DNA and RNA analysis. Viral DNA preparation and Southern blot analysis of viral DNA with a gIII-specific 32P-labeled probe were performed as described previously (15, 17) . For DNA sequencing, a 1.1-kbp XhoI-KpnI fragment containing the putative promoter and 5'-coding sequence of glll was cloned into M13mpl8. The dideoxy method (19) was used to sequence the glll promoter and signal sequence coding region with a synthetic oligonucleotide primer that hybridized upstream of the gene (6) .
The isolation of total cytoplasmic RNA from infected cells and subsequent Northern (RNA) and slot-blot analysis were conducted as previously described (6, 17) .
The in vitro translation of total cytoplasmic RNA obtained from PRV-infected cells has been described previously (17) . Translated extracts were resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis or used for the immunoprecipitation of glll-specific proteins with 282 antiserum (18 (18) . The preparation of infected cell extracts and the immunoprecipitation procedure have been described previously (18) . As indicated in the text, some samples were denatured by boiling prior to adding antibody to improve 282 serum reactivity.
Antibody reagents. The antibodies used in these studies included mouse monoclonal antibodies Ml and M16 (reactive only against the native glycosylated forms of gIll; these antibodies do not react with in vitro-translated gIll or intracellular nonglycosylated gIll [6, 9] ), goat polyvalent anti-gIll antiserum 282 (reactive with both native and denatured forms of glycosylated or nonglycosylated gIll [18] ), and goat polyvalent anti-gII antiserum 284 and mouse monoclonal antibody M3 (both reactive only against the gII family of glycoproteins [9, 18] Black-plaque assay. The black-plaque assay has been described previously (6) .
RESULTS
Rationale. We sought to determine the cause of the apparent low gIll expression by attenuated vaccine strain PRVBa. We reasoned that such an expression defect could either be linked to the gIII gene itself or be caused by one of the many known defects of PRV-Ba. We therefore deleted the gIII gene and its promoter from PRV-Be, a strain containing a well-characterized and fully expressed gIII gene (6, 63, 1989 strategy is described in Fig. 1 and in Materials and Methods. PRV-Be, PRV-Ka, and PRV-Ba all expressed detectable amounts of gIll on the surface of infected cells since these viruses formed black plaques with glll-specific Ml monoclonal antibody. We used this observation to screen for isogenic viruses with the desired gIII gene replacement after cotransfection of PRV10 (17) with cloned fragments encoding the glll genes of PRV-Be, PRV-Ba, PRV-Ka. The high frequency of gene replacement (>5%) reflected the strong growth advantage of viruses expressing gIII over viruses lacking a functional gIII gene (22) . The isogenic set of viruses derived was PRV20 (gIII gene of PRV-Be), PRV21 (gIll gene of PRV-Ka), and PRV22 (gIll gene of PRV-Ba). The viral DNA was digested with a variety of restriction enzymes and analyzed by Southern blot hybridization with the 32P-labeled 4.3-kbp PstI fragment of PRV-Be. With the exception of SacI, no restriction fragment polymorphisms were detected (data not shown). Both gIII-Be (PRV-Be or PRV20) and gIII-Ba (PRV-Ba or PRV22) contained two apparently identical Sacl sites within the body of the gene, while gIII-Ka (PRV-Ka or PRV21) contained an additional Sacl site. Fragments from all viruses hybridizing to the PRV-Be gIII probe appeared with the same intensity, indicating no major sequence divergence. There were no obvious deletions or rearrangements of the 4.3-kbp PstI fragment among the viruses.
Analysis of total cytoplasmic RNA from PRV-infected cells. To determine whether transcription of the gIII gene was altered in PRV-Ba or PRV22, we studied the quantity and quality of glll-specific RNA by using Northern blot and slot-blot techniques. Total cytoplasmic RNA was extracted from PK15 cells infected with the indicated viruses. Estimation of the quantity of glll-specific RNA was accomplished with a slot-blot format. The purified RNA (10 ,ug) was serially diluted twofold, denatured, and transferred to nitrocellulose membranes in a slot-blot apparatus as described in Materials and Methods. The quality of glll-specific RNA was determined by Northern blotting. For these studies, 5 ,ug of each RNA sample was analyzed as described in Materials and Methods. The radioactive probe used for both blots was an NcoI-BamHI fragment containing only gIII gene sequences from PRV-Be.
Autoradiograms of the slot blots ( Fig. 2 ) are shown. The slot-blot analysis indicated that the amount of steady-state gIII-specific RNA was nominally the same for all viruses tested. The experiment has been repeated using RNA prepared at different times after infection with similar results (data not shown). The Northern blot analysis indicated that an identically sized species of gIII-specific RNA comigrating with the 1.55-kilobase PRV-Be RNA was found for all viruses (data not shown).
In vitro translation of total RNA extracted from infected PK15 cells. The same RNA analyzed by slot-blot and Northern analysis was used for in vitro translation experiments (Fig. 3) . RNA from uninfected cells was included as a control. The polypeptides translated in vitro were labeled with [35S]methionine. Either in vitro-translated samples were fractionated directly on a 10% polyacrylamide-SDS gel (Fig. 3 , left panel), or gIII-specific translation products were immunoprecipitated with polyvalent 282 serum and then fractionated on a 10% polyacrylamide-SDS gel (Fig. 3 , right panel). Translation products from uninfected cell RNA are in lanes marked C.
By examining the intensity of bands in the nonimmunoprecipitated samples ( RNA, although the pattern for PRV-Ba is distinctly different from that for PRV-Be or PRV-Ka. For the isogenic strains, PRV20, PRV21, and PRV22, the patterns were identical to that found for PRV-Be, as expected. It is noteworthy that a novel protein product tightly linked to gIII appeared to be altered in both PRV-Ka and PRV-Ba. This is best seen in the left panel comparing the last three isogenic samples. The profiles are identical except for the indicated band (shown by a dot) migrating slightly faster for PRV21 and PRV22, but not PRV20. The identity of this protein is unknown.
It is clear that for all viruses, 282 antiserum immunoprecipitated proteins of approximately 58-kilodaltons, characteristic of the predicted 479-amino-acid gIII primary translation product (15, 17). However, for PRV-Ka, PRV-Ba, and the isogenic strains PRV21 and PRV22, the primary translation product migrated slightly faster than that from PRV-Be or PRV20. This may reflect differences in amino acid composition or may indicate that the genes contain small inframe deletions. Compared with the amount of PRV-Be gIII immunoprecipitated by 282 serum, both PRV-Ba and PRV22 RNA yielded about two-to threefold-reduced amounts of immunoreactive gIII. Given that the amounts of gIII-specific RNA in these preparations were essentially identical (Fig.  2) , this result suggests a lower translation efficiency of the PRV-Ba gIII message in the rabbit reticulocyte system.
Immunoprecipitation of glucosamine-labeled PRV-specific proteins from virus particles. PK15 cells were infected with PRV-Be, PRV-Ka, PRV-Ba, PRV20, PRV21, or PRV22 as described in Materials and Methods. [3H]glucosamine was added at the time of infection to label the glycoproteins. After 16 h, medium containing extracellular virus particles was collected and the virus was purified by centrifugation and analyzed as described in Materials and Methods. Remaining infected cells were used in the subsequent experiment. The purified virus particles were analyzed directly or lysed and reacted with gIII-or gll-specific antibodies. The immunoprecipitates were collected and fractionated on a 10% polyacrylamide-SDS gel. The 3H-labeled polypeptides detected by fluorography are displayed in Fig. 4 .
The gIII defect of PRV-Ba is demonstrated in compared with PRV-Be or PRV-Ka. The defect was elaborated, if not more severe, in the isogenic derivative PRV22 (compare PRV22 with PRV20 or PRV21) and therefore is tightly linked to the PRV-Ba gIl gene itself. Note that in this experiment, fewer PRV-Be virions were recovered after purification. This can be deduced by examining the intensity of the bands in Fig. 4D , the control profiles of the gll protein immunoprecipitated from the same sample, or, from Fig. 4E , the total glucosamine-labeled profiles of purified virus particles. It has been reported that PRV-Ba-encoded gIII does not react with a second glll-specific monoclonal antibody, M16 (2) . This lack of reactivity is clearly demonstrated in Fig. 4B for both parental PRV-Ba and the isogenic strain, PRV22. Figure 4C shows the reactivity with polyvalent 282 antiserum. Note that PRV-Ba and its isogenic derivative PRV22 reacted with this serum, although the amount of gIII protein precipitated was reduced. This reduction is best seen in the comparison of the isogenic strains. Figure 4D is a control immunoprecipitation of the gIl family of glycoproteins from the same virion samples to indicate efficiency of infection and sample recovery.
The experiment in Fig. 4B indicated that the PRV-Ba gIII protein lacked the M16 epitope. This observation could indicate that the PRV-Ba glll protein, rather than being poorly expressed, was simply less immunoreactive in general with gIII-specific antisera. However, the data in Fig. 4E strongly suggested that the gIII protein of PRV-Ba was present in physically lower amounts in purified virions. In this experiment, purified [3H]glucosamine-labeled virions were fractionated directly on a 10% polyacrylamide-SDS gel with no immunoprecipitation. Compare the last three lanes containing the isogenic strains and note the reduction of intensity of the 92-kDa species for PRV22 and PRV-Ba.
We conclude that the apparent reduced expression phenotype of gIll seen for PRV-Ba is tightly linked to the gIII gene, and in addition, we corroborate the observations of Ben-Porat et al. (2) that the PRV-Ba gIII gene encodes a mutant glycoprotein with altered immunoreactivity to the M16 monoclonal antibody.
Immunoprecipitation of glucosamine-labeled, PRV-specific proteins from infected PK15 cells. In the previous experiment, we showed that PRV-Ba glll protein is reduced in virus particles. The next set of experiments examined the infected cells from the same infection. The experiment was done as described above. After removal of the medium, the infected cells were lysed (see Materials and Methods) and reacted with gIII-or gll-specific antibodies. The immunoprecipitates were collected and subsequently fractionated on a 10% polyacrylamide-SDS gel. The 3H-labeled polypeptides detected by fluorography are displayed in Fig. 5 . Figure 5A shows that all viruses produced mature glll in infected cells reactive with Ml monoclonal antibody, although PRV-Ba and PRV22 consistently gave lower amounts. The faster-migrating band of 62 kDa, more predominant in PRV-Ba-infected cells (indicated by a dot), was seen in the other infections as well after longer exposures. It was not seen with M16 monoclonal antibody or with 282 polyvalent serum. It could also be precipitated from [35S]cysteine-labeled cell extracts by using only Ml monoclonal antibody (see below). Its relationship to gIll, if any, is currently not understood.
The M16 monoclonal antibody recognizes not only the mature 92-kDa form of gIII, but also the 74-kDa precursor (18) . Although PRV-Be, PRV-Ka, and their isogenic derivatives gave indistinguishable patterns of immunoprecipitated glll protein, PRV-Ba and PRV22 had no detectable reactivity with this antibody (shown in Fig. SB The polyvalent glll antiserum 282 reacts with both the precursor and the mature form of gIII for a variety of gIll mutants (6, 18; Ryan et al., in press). The data given in Fig.  5C demonstrate that all viruses produced precursor and mature forms of glll reactive with this sera, although PRVBa and PRV22 clearly produced less 74-kDa protein. The critical comparison is of the isogenic strains in the last three lanes of Fig. 5C . It is clear that PRV22 produced less immunoreactive precursor and mature glycosylated gIII protein than either PRV20 or PRV21.
The control immunoprecipitations of gll glycoprotein (Fig. 5D) were similar, indicating that all infections had progressed essentially to the same state. The 100-kDa precursor form, not seen in purified virions (Fig. 4D) , was precipitated for all viruses. We note that the gll profile from PRV-Ba, but not PRV22, was slightly different qualitatively and quantitatively from all other viruses as observed previously (2), suggesting that PRV-Ba has mutations in gll as well (see Discussion).
Immunoprecipitation state labeling experiments was done with [35S]cysteine rather than [3H]glucosamine as the label. The experiment will detect all stable gIlI-immunoreactive species, including those that are not glycosylated. Cells were infected with PRV-Be, PRV-Ba, or PRV22, labeled from 6 to 16 h postinfection as described in Materials and Methods, and subsequently fractionated into released virions and infected cells.
Extracts of infected cells or virions were reacted with anti-gIII-specific antibodies, and immunoprecipitates were collected and then fractionated on a 10% polyacrylamide-SDS gel. The 35S-labeled polypeptides were detected by fluorography. The results with infected cell extracts are shown in Fig. 6 .
Ml monoclonal antibody immunoprecipitated the mature 92-kDa form of gIll from each infected cell extract. However, both PRV-Ba-and PRV22-infected cells clearly contained less immunoreactive protein, consistent with previous observations for [3H]glucosamine-labeled infected cells (Fig.  4) (Fig. 4) .
282 serum immunoprecipitated only the 92-kDa mature form and the 74-kDa precursor form of glll from PRV-Beinfected cells. In contrast, a significant fraction of the 282-reactive "S-labeled polypeptides in PRV-Ba-or PRV22-infected cells migrated with an apparent molecular mass of 58 kDa. This species was not apparent in similar experiments with [3H]glucosamine labeling (Fig. 4) . The normal 92-kDa mature form and the 74-kDa precursor species were present, but at reduced levels.
The profiles for [35S]cysteine-labeled virions were also examined (data not shown). The results were essentially identical to those obtained for [3H]glucosamine-labeled virions (Fig. 4) in that both PRV-Ba and PRV22 virions contained less cysteine-labeled gIII than PRV-Be did.
We conclude that the [3H]glucosamine-and [35S]cysteinelabeled gIll profiles from infected cells are essentially identical with one major exception.PRV-Ba-and PRV22-infected cells contain a new, 58-kDa major species labeled only with [35S]cysteine and reactive only with 282 serum. We suggest that this species is a product of the PRV-Ba glll gene because it is produced by PRV22 and not PRV-Be.
Pulse-chase analysis of gIll protein. The long-term labeling experiment presented above defines stable gIII species whose intensity of labeling is dictated by synthesis rate and turnover rate. The following experiment examined the rates of synthesis and stability of teins produced by the virus strains and determined whether any transient, processed forms of the protein existed in the infected cell that might not be detected under steady-state radiolabeling conditions. Of particular interest was the 58-kDa gIll species made by PRV-Ba and PRV22 seen in steady-state [35S]cysteine labeling (Fig. 6 ), but not in [3H] glucosamine labeling (Fig. 4 and 5 ). PK15 cells were infected with PRV-Be, PRV-Ba, and PRV22. A pulse-chase experiment with [35S]cysteine was performed at 4 h postinfection as described in Materials and Methods. gIII-specific proteins were immunoprecipitated with polyvalent 282 serum. The results are shown in Fig. 7 .
As noted previously (6, 18; Ryan et al., in press), the initial product of glll translation observed in a 2-min pulse for PRV-Be was the 74-kDa species known to be modified by high-mannose, N-linked glycosylation characteristic of a VOL. 63, 1989 location in the endoplasmic reticulum. Export of PRV-Be gIII from the endoplasmic reticulum to the Golgi apparatus was rapid and efficient; the 92-kDa mature form appeared as early as 30 min after pulse-labeling, and only a small fraction of the 74-kDa precursor remained after a 1-h chase.
The pulse-chase profile obtained for PRV-Ba or PRV22 was strikingly different. First, the predominant primary translation product observed after the 2-min pulse was a 58-kDa form. The 74-kDa form was present but barely detectable. The small quantity of 74-kDa protein chased to the mature 92-kDa species with essentially identical kinetics as PRV-Be-encoded gIII. The 58-kDa species remained essentially constant during the first 2 h of the chase period but showed significant loss of signal toward the end of the 8-h chase. We were struck by the similarity between the PRV-Ba and PRV22 pulse-chase profiles and those found for defined glll signal sequence mutants of PRV-Be constructed by Ryan et al. (in press). Certain signal sequence mutations partially block cotranslational export of the gIII protein from the cytoplasm to the endoplasmic reticulum. The 58-kDa form is believed to be the authentic, nonglycosylated-primary translation product as identified by in vitro translation (6, 15, 17; Ryan et al., in press).
For PRV-Ba and PRV22, the intense labeling of the 58-kDa form compared with other forms of gIII is noteworthy. We note that the amount of cysteine available to the cells during the 2-min pulse was not in excess (addition of more radioactive cysteine resulted in more incorporation [unpublished observations]). Therefore, the intensity of label in the 58-kDa species suggests that it was being synthesized at an increased rate compared with the 74-kDa glycosylated precursor.
We conclude from these experiments that the gIII gene of PRV-Ba and PRV22 contains a defect giving rise to a novel primary product of translation not characteristic of the membrane-bound glycosylated 74-kDa precursor. The major species of gIII observed in a 2-min pulse at 4 h postinfection is a 58-kDa protein with the same apparent mass as the in vitro-translated gene product. This species is translated at an increased rate compared with the normal 74-kDa precursor. The reduced amount of normal 74-kDa precursor made is converted to mature 92-kDa product at the same rate as normal gIll and appears with time in virus particles (data not shown). The PRV-Ba 58-kDa aberrant gIII precursor is a dead-end product and slowly turns over. We cannot compare directly the amount of 58-kDa precursor seen in steadystate labeling (Fig. 6) (3, 5, 7, 8, 10, 11, 13, 14, 20, 21) . One well-known but poorly characterized phenotype of the PRV-Ba strain is the apparent low-level expression of glycoprotein gIll (2) .
We It is important to note that the site-directed gIll signal sequence mutation at codon 12 described by Ryan et al. (in press ) affects the hydrophobic domain of the signal sequence by introducing a charged amino acid. The change in PRV-Ba gIll at codon 14 introduces proline, a neutral amino acid that will alter the predicted alpha-helix structure of this domain, but should have little effect on the hydrophobic content. Work is in progress to determine the role of the hydrophobic region in gIII signal sequence function (J. P. Ryan, M. E.
Whealy, A. K. Robbins, and L. W. Enquist, manuscript in preparation).
Why would such a specific defect occur during the process of making the attenuated vaccine strain? Is the signal sequence mutation due to chance occurrence or could there be some rationale for its appearance? Most work must be done to understand the role of gIII in the life cycle of PRV before these questions can be answered. Nevertheless, it is clear that a signal sequence mutation represents one simple way to lower, but not totally deplete, the amount of gIll protein in virus envelopes or on the surface of infected cells without affecting the mature protein structure. Reducing the amount of intracellular gIll that can enter the protein export pathway clearly leads to production of virions with reduced gIll in their envelopes. With defined signal sequence mutations, we can determine whether simply lowering the amount of mature gIII is sufficient for decreased virulence. By correcting the signal sequence mutation in PRV-Ba gIll, it will be possible to determine whether the additional mutation(s) in the body of the gene affecting antibody recognition plays a role in virus release and virulence.
Schreurs et al. (20) suggested that roles in virus adsorption and release from infected cells constituted separate functions of the gIll protein. One line of evidence supporting this hypothesis was that PRV-Ba, despite its reduced complement of gIll in virions, absorbed normally to cells yet was defective in release of virus. The implication was that the PRV-Ba gIII protein was defective in one domain affecting release, while the adsorption domain remained intact. Our finding that the PRV-Ba gIII gene harbors a signal sequence mutation suggests an alternative testable hypothesis. Perhaps the processes of adsorption and virus release differ with respect to their concentration dependence on mature gIII. For example, the process of efficient virus absorption to cells could require very little gIll protein per virion, while the process of virus release could be more dependent on gIll concentration or could involve more gIll-dependent steps. A test of this hypothesis would be that reversion of the codon 14 mutation in PRV-Ba gIll (if it restored normal levels of gIII in the virus envelope) would result in a virus with normal kinetics of virus release.
Our studies support and extend previous observations indicating that other alterations exist in PRV-Ba. In general, we found that PRV22 was more defective than the parental PRV-Ba or PRV-Be strains in the glll phenotypes measured. This suggests that the PRV-Ba glll protein functions well only in the PRV-Ba background, perhaps indicating that PRV-Ba has developed compensatory mechanisms to deal with its altered gIII protein. As suggested by Ben-Porat et al. (2) 
